HUMA
HumacyteยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
HUMA Profile
Humacyte, Inc.
A clinical-stage biotech platform company that develops universally implantable bioengineered human tissues, complex tissue systems, and organs
Biological Technology
07/01/2020
12/01/2020
NASDAQ Stock Exchange
218
12-31
Common stock
2525 East North Carolina Highway 54, Durham, North Carolina 27713
--
Humacyte, Inc., was incorporated in Delaware on July 1, 2020. The company is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissue, advanced tissue structures and organ systems with the goal of improving the lives of patients and transforming medical practice. The company is utilizing a novel, scalable technology platform to develop proprietary bioengineered cell-free human tissue for the treatment of diseases and conditions at a range of anatomical locations across multiple therapeutic areas.
